IRCT20230312057691N1招募中Unknown
Clinical evaluation of 68Ga-SSSLTVSPWY peptide for evaluation of HER2 overexpression status in patients with breast cancer with PET/CT and compare to 18FDG
适应症
试验速览
- 阶段
- Unknown
- 状态
- 招募中
- 入组人数
- 25
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- no limit 至 no limit（—）
- 性别
- Female
入选标准
- •Patients with HER2-overexpressed breast tumors (primary or metastatic mass) after screening with IHC test (with 3+ result) or FISH test
排除标准
- •Breastfeeding
- •Uncontrolled kidney and liver disorders
- •A history of allergy to radiopharmaceuticals
研究者
相似试验
已完成
不适用
Clinical evaluation of the SSSLTVPWY peptide labeled with 99m TCbreast cancer.Malignant neoplasm of breast of unspecified site, femaleC50.91IRCT20180310039019N1Mazandaran University of Medical Sciences25
已完成
1 期
Phase I/II clinical study of WT4869 peptide-based immunotherapy in patients with completely resected stage IA with vascular invasion, stage IB and stage II non-small cell lung cancer with WT1 antigen positive.Completely resected NSCLC, stage IA with vascular invasion and stage IB/II with WT1 antigen positive.JPRN-UMIN000010027Osaka University Graduate School of Medicine, Department of Functional Diagnosis237
已完成
不适用
OTSGC-A24 therapeutic peptide Vaccine + Nivolumab – a combination immunotherapy Phase Ib study for inoperable or metastatic gastric cancer.NeoplasmsKCT0005481Yonsei University Health System, Severance Hospital7
已完成
2 期
Phase II Clinical trial of personalized peptide vaccine for cancer patients - Effect of extended dose interval on the immun inductionmalignant tumorJPRN-UMIN000006927Kurume University Cancer Vaccine Center60
已完成
2 期
Phase II Clinical trial of personalized peptide vaccine for cancer patientsmalignant tumorJPRN-UMIN000001482Kurume University Cancer Vaccine Center150